R&D channel feed

In small ac­qui­si­tion, Ab­b­Vie adds Lan­dos and its IBD drug to post-Hu­mi­ra plans

Last year
Deals

Nkar­ta drops a can­cer pro­gram, putting au­toim­mune front and cen­ter. Will it pay off?

Last year
Cell/Gene Tx

Mer­ck re­ports an­oth­er fail­ure for Keytru­da-Lyn­parza com­bo in non-small cell lung can­cer

Last year
Pharma

De­spite Phase 3 win, Roche says rare au­toim­mune drug did­n't meet ex­pec­ta­tions

Last year

Gal­der­ma tar­gets one of this year's biggest Eu­ro­pean IPOs with top-of-the-range share price

Last year
Financing

The Op­di­vo-Yer­voy com­bo from Bris­tol My­ers is work­ing to­ward ap­proval in first-line liv­er can­cer

Last year
Pharma

David Bak­er’s lab shows gen­er­a­tive AI can de­sign an­ti­bod­ies. But are they good enough to be­come drugs?

Last year
AI

As fo­cus shifts to on­col­o­gy, BioN­Tech nabs No­var­tis ex­ec as chief com­mer­cial of­fi­cer

Last year
People

Lab­corp ex­pands Alzheimer’s blood tests for doc­tors and drug­mak­ers

Last year
Pharma

Ace­lyrin crew be­hind first thy­roid eye dis­ease med­i­cine builds its po­ten­tial com­peti­tor, with ear­ly da­ta to boast

Last year

High­ly-await­ed PhI­II study of Gates-backed tu­ber­cu­lo­sis vac­cine un­der­way

Last year

Cri­net­ics re­ports sec­ond PhI­II win for acromegaly drug, eyes 2025 launch

Last year

With pos­i­tive PhI­II da­ta in hot flash­es, Bay­er is a step clos­er to chal­leng­ing Astel­las’ Veozah

Last year

No­vo Nordisk Foun­da­tion backs ef­fort to build su­per­com­put­er with Nvidia

Last year
AI

GSK’s new PhI­II da­ta sup­port bid for wider en­dome­tri­al can­cer la­bel for Jem­per­li

Last year
Pharma

Spruce Bio­sciences’ stock plum­mets in wake of PhI­Ib flop, biotech to cut staff

Last year
People

As­traZeneca eyes rare en­docrinol­o­gy mar­ket with $1.05B buy­out of Amolyt Phar­ma

Last year
Deals

Si­lence re­ports pos­i­tive PhII cho­les­terol drug da­ta, re­veals end to Mallinck­rodt al­liance

Last year
Deals

Io­n­is touts PhII MASH study da­ta that fea­ture its DGAT2 an­ti­sense in­hibitor

Last year

Sanofi to shut­ter ex-Kymab R&D fa­cil­i­ty in the UK

Last year
People

Cri­net­ics’ car­ci­noid syn­drome drug gears up for reg­is­tra­tional test af­ter PhII da­ta up­date

Last year

Topline Ad­cetris da­ta in blood can­cer could mean new in­di­ca­tion for Pfiz­er

Last year
Pharma

Roche is try­ing again and again in Alzheimer’s. This time, ear­ly da­ta are ‘worth watch­ing’

Last year

Bris­tol My­ers drops an­oth­er Cy­tomX pro­gram

Last year
First page Previous page 48495051525354 Next page Last page
A service from the Financial Times